Why Is Long-Term Therapy Required to Cure Tuberculosis?

por Connolly, Lynn E, Edelstein, Paul H, Ramakrishnan, Lalita
Publicado 2007

Comprehensive Functional Analysis of Mycobacterium tuberculosis Toxin-Antitoxin Systems: Implications for Pathogenesis, Stress Responses, and Evolution

por Ramage, Holly R., Connolly, Lynn E., Cox, Jeffery S.
Publicado 2009

A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection a...

por Connolly, Lynn E., Riddle, Valerie, Cebrik, Deborah, Armstrong, Eliana S., Miller, Loren G.
Publicado 2018

1964. Microbiological Outcomes With Plazomicin (PLZ) vs. Colistin (CST) in Patients With Bloodstream Infections (BSI) Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) in the...

por Serio, Alisa W, Smith, Alex, Krause, Kevin M, Galani, Irene, Gales, Ana Cristina, Jubb, Adrian, Connolly, Lynn E
Publicado 2018

1089. Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclon...

por Van Wart, Scott A, Tarbell, Evan D, Narayan, Kristin, Walker, Laura M, Connolly, Lynn E, Ambrose, Paul G
Publicado 2021

633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an...

por Paguntalan, Helen, Magyarics, Zoltán, Connolly, Lynn E, Hershberger, Ellie, Narayan, Kristin, Gupta, Deepali, Ambrose, Paul G, Engler, Frank, Campanaro, Ed, Das, Anita F, Schmidt, Pete
Publicado 2021

1088. A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Anti...

por Tarbell, Evan D, Van Wart, Scott A, Shah, Dhaval K, Walker, Laura M, Santulli, Andrew, Connolly, Lynn E, Mager, Donald E, Brown, Ashley N, Ambrose, Paul G
Publicado 2021

Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)

por Ison, Michael G, Weinstein, Debra F, Dobryanska, Marta, Holmes, Anna, Phelan, Anne-Marie, Li, Yong, Gupta, Deepali, Narayan, Kristin, Tosh, Kazima, Hershberger, Ellie, Connolly, Lynn E, Yalcin, Ilker, Campanaro, Ed, Hawn, Pamela, Schmidt, Pete
Publicado 2023

Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized,...

por Ison, Michael G, Popejoy, Myra, Evgeniev, Nikolay, Tzekova, Maria, Mahoney, Kathryn, Betancourt, Natalia, Li, Yong, Gupta, Deepali, Narayan, Kristin, Hershberger, Ellie, Connolly, Lynn E, Yalcin, Ilker, Das, Anita F, Genge, John, Smith, Michelle, Campanaro, Ed, Hawn, Pamela, Schmidt, Pete
Publicado 2023